Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Profiling genomico nei pazienti oncologici

23 settembre 2026 aggiornato da: Memorial Sloan Kettering Cancer Center

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

200

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: David Solit, MD
  • Numero di telefono: 646-888-2641

Backup dei contatti dello studio

  • Nome: Zsofia Stadler, MD
  • Numero di telefono: 646-888-4039

Luoghi di studio

    • Connecticut
      • Bridgeport, Connecticut, Stati Uniti, 06606
        • Non ancora reclutamento
        • St. Vincent (Data Collection Only)
        • Contatto:
          • Christopher Iannuzzi, MD
          • Numero di telefono: 203-576-6000
      • Hartford, Connecticut, Stati Uniti, 06102
        • Non ancora reclutamento
        • Hartford Healthcare Cancer Institute @ Hartford Hospital
        • Contatto:
          • Andrew Salner, MD
          • Numero di telefono: 860-972-2803
      • Norwalk, Connecticut, Stati Uniti, 06850
        • Reclutamento
        • Norwalk Hospital
        • Contatto:
          • Linda Vahdat, MD
          • Numero di telefono: 203-845-4811
    • Florida
      • Miami, Florida, Stati Uniti, 33143
        • Reclutamento
        • Baptist Alliance MCI
        • Contatto:
          • John Diaz, MD
          • Numero di telefono: 786-596-2000
    • New Jersey
      • Basking Ridge, New Jersey, Stati Uniti, 07920
        • Reclutamento
        • Memorial Sloan Kettering Basking Ridge
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
      • Middletown, New Jersey, Stati Uniti, 07748
        • Reclutamento
        • Memorial Sloan Kettering Monmouth
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
      • Montvale, New Jersey, Stati Uniti, 07645
        • Reclutamento
        • Memorial Sloan Kettering Bergen
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
    • New York
      • Brooklyn, New York, Stati Uniti, 11203
        • Reclutamento
        • Kings County Hopsital Center
        • Contatto:
          • Jason Gonsky, MD
          • Numero di telefono: 718-245-2847
      • Commack, New York, Stati Uniti, 11725
        • Reclutamento
        • Memorial Sloan Kettering Cancer Commack
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
      • Harrison, New York, Stati Uniti, 10604
        • Reclutamento
        • Memorial Sloan Kettering Westchester
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
      • Jamaica, New York, Stati Uniti, 11432
        • Reclutamento
        • Queens Cancer Center of Queens Hospital
        • Contatto:
          • Debra Ferman, MD
          • Numero di telefono: 718-579-6021
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
        • Contatto:
          • Zsofia Stadler, MD
          • Numero di telefono: 646-888-4039
        • Investigatore principale:
          • David Solit, MD
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Metropolitan Hospital Center
        • Contatto:
          • Anitha Srinivasan, MD
          • Numero di telefono: 212-423-6262
      • New York, New York, Stati Uniti, 10035
        • Reclutamento
        • Ralph Lauren Center for Cancer Care and Prevention
        • Contatto:
          • Lewis P. Kampel, MD
          • Numero di telefono: 646-422-4474
      • Richmond Hill, New York, Stati Uniti, 11418
        • Reclutamento
        • Medisys Health Network (Data Collection Only)
        • Contatto:
          • Rosa Nouvini, MD
          • Numero di telefono: 718-206-6000
      • The Bronx, New York, Stati Uniti, 10451
        • Reclutamento
        • NYC Health & Hospitals /Lincoln Medical Center
        • Contatto:
          • Monica Reddy Muppidi, MD
          • Numero di telefono: 718-579-4977
        • Investigatore principale:
          • Monica Reddy Muppidi, MD
      • Uniondale, New York, Stati Uniti, 11553
        • Reclutamento
        • Memorial Sloan Kettering Nassau
        • Contatto:
          • David Solit, MD
          • Numero di telefono: 646-888-2641
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Reclutamento
        • Lehigh Valley Health Network
        • Contatto:
          • Suresh Nair, MD
          • Numero di telefono: 610-402-7880

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients with solid or hematologic cancers who may be and considered potential candidates for a therapeutic protocol will be recruited to Part A of this study. Enrollment to therapeutic clinical trials will not be contingent on enrollment in this protocol.

Part B: Research Collection Cohort Patients potentially appropriate will be identified by their treating physician in each participating Disease Management Team.

Descrizione

Inclusion Criteria:

Part A:

  • Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
  • Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
  • Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.

Part B:

  • Patients must be successfully registered to Part A of MSKCC IRB# 12-245
  • Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
  • Patient must have successfully consented to Part A of this study.

Part D:

  • Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion Criteria:

All Parts:

  • Unwilling or unable to provide informed consent.

Part C:

  • All patients consenting to Part A are eligible to consent to 12-245, Part C. Most patients will be eligible to receive clinical germline testing with return of results to the patient/health care providers. However, several exclusion criteria apply and are outlined below

    1. Solid tumor patients: Secondary germline analysis using BAM files generated for MSK-IMPACT testing is not an option for patients with solid tumors and an acute or chronic hematologic neoplasm that would preclude the use of blood or saliva as a source of germline DNA. Such patient may be eligible for primary germline testing using a non-blood source of germline DNA as per standard clinical guidelines. Solid tumor patients who have had an allogenic bone marrow/stem cell transplant will only be considered eligible for germline testing under Part C if a sample adequate for germline testing had previously been collected prior to allogenic bone marrow/stem cell transplant.
    2. Hematologic cancer patients: For patients with a hematopoietic neoplasm, germline testing may be an option under Part C using nail clippings or another non-blood source of DNA as per standard clinical practice. For patients who have had an allogenic bone marrow/stem cell transplant, clinical germline testing will only be considered under Part C if a sample adequate for germline testing had previously been collected prior to Allogenic bone marrow/stem cell transplant.

Part D

  • Exclusion criteria are same as those for Part C outlined above.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Pts with solid tumors

Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.

Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.

Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").

Part D: Germline Profiling for Individuals at Elevated Cancer Risk

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
frequency of "actionable" oncogenic mutations
Lasso di tempo: 1 year

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

1 year

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.
Lasso di tempo: 1 year

The Bioinformatics Core will assist in interpreting data generated by next-generation sequencing techniques such as WES and WGS.

1 year
interrogate the mechanisms
Lasso di tempo: 1 year

underlying response and resistance (de-novo and acquired) to targeted therapy. The research assay(s) used to accomplish this will vary based on the clinical setting and tissue available and may include Sanger, Sequenom, MiSeq, exon-capture (ie: IMPACT), whole exome, and whole genome sequencing.

1 year
To explore the genetic mechanisms of tumorigenesis
Lasso di tempo: 2

in a subset of specimens with no identifiable culpritic genomic alterations on highly-multiplexed next-generation sequencing (i.e.: IMPACT testing) by using even more comprehensive investigational profiling techniques such as whole exome sequencing, whole genome sequencing or RNA sequencing

2

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: David Solit, MD, Memorial Sloan Kettering Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 gennaio 2013

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 gennaio 2027

Date di iscrizione allo studio

Primo inviato

21 gennaio 2013

Primo inviato che soddisfa i criteri di controllo qualità

21 gennaio 2013

Primo Inserito (Stimato)

24 gennaio 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 12-245

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .